Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Background: The approval of immune checkpoint inhibitors in combination with specific diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs to be tested for expression of programmed death-ligand 1 (PD-L1) for a variety of indications. As there is currently no requiremen...

Full description

Bibliographic Details
Main Authors: Julika Ribbat-Idel, Franz F. Dressler, Rosemarie Krupar, Christian Watermann, Finn-Ole Paulsen, Patrick Kuppler, Luise Klapper, Anne Offermann, Barbara Wollenberg, Dirk Rades, Simon Laban, Markus Reischl, Karl-Ludwig Bruchhage, Christian Idel, Sven Perner
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Medicine
Subjects:
HNSCC
PD-L1
checkpoint inhibitors
TMA
harmonization
therapy prediction
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.640515/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.640515/full

Similar Items